List view / Grid view
26 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
26 October 2012 | By F T I Consulting
Melbourne researchers have developed cows’ milk that can protect human cells from human immunodeficiency virus (HIV)...
26 October 2012 | By Boehringer Ingelheim
Successful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung...
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
25 October 2012 | By Novartis
Confidence in the safety and efficacy of seasonal influenza vaccines...
25 October 2012 | By Novo Nordisk
“This meeting will focus on the cardiovascular safety of two products..."
24 October 2012 | By Energy PR
The British Laboratory Managers Association is being launched by GAMBICA...
24 October 2012 | By Abbott
ALK test now available in Europe...
24 October 2012 | By Pfizer
Conditional marketing authorization for XALKORI® in the EU granted...
24 October 2012 | By Abbott
"These data suggest that adalimumab-treated patients were able to reduce steroid usage..."
23 October 2012 | By Merck
New Phase III study presented...
23 October 2012 | By Abbott
Results from a post-hoc sub-analysis...
23 October 2012 | By AstraZeneca
AstraZeneca and Ironwood Pharmaceuticals, Inc. announced an agreement to co-develop and co-commercialise Ironwood’s linaclotide...
23 October 2012 | By kdm communications limited
Avacta Analytical’s Optim® 1000 is proving a valuable asset to scientists at the MVSC, University of Kansas, USA...
Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.
